ChengDa Pharmaceuticals (301201) Stock Overview
Engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
301201 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
ChengDa Pharmaceuticals Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥43.77 |
| 52 Week High | CN¥61.11 |
| 52 Week Low | CN¥18.00 |
| Beta | 0.23 |
| 1 Month Change | 5.39% |
| 3 Month Change | 23.02% |
| 1 Year Change | 131.71% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 49.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301201 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -14.3% | -1.9% | 0.4% |
| 1Y | 131.7% | 24.4% | 34.6% |
Return vs Industry: 301201 exceeded the CN Pharmaceuticals industry which returned 24.4% over the past year.
Return vs Market: 301201 exceeded the CN Market which returned 34.6% over the past year.
Price Volatility
| 301201 volatility | |
|---|---|
| 301201 Average Weekly Movement | 12.2% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in CN Market | 9.4% |
| 10% least volatile stocks in CN Market | 2.9% |
Stable Share Price: 301201's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 301201's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 656 | Gang Lu | www.chengdapharm.com |
ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, muscular system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates.
ChengDa Pharmaceuticals Co., Ltd. Fundamentals Summary
| 301201 fundamental statistics | |
|---|---|
| Market cap | CN¥6.63b |
| Earnings (TTM) | -CN¥51.72m |
| Revenue (TTM) | CN¥374.46m |
Is 301201 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301201 income statement (TTM) | |
|---|---|
| Revenue | CN¥374.46m |
| Cost of Revenue | CN¥225.40m |
| Gross Profit | CN¥149.06m |
| Other Expenses | CN¥200.78m |
| Earnings | -CN¥51.72m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 28, 2026
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 39.81% |
| Net Profit Margin | -13.81% |
| Debt/Equity Ratio | 2.7% |
How did 301201 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/19 20:14 |
| End of Day Share Price | 2026/01/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ChengDa Pharmaceuticals Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.